Executive interview with Erik Manting PhD, CEO of Mendus

In this video, Soo Romanoff, healthcare managing director of Edison Group, interviews Erik Manting, CEO of Mendus.

Mendus is a clinical-stage immunoncology (IO) company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell biology and is developing durable off-the-shelf therapies for haematological and solid tumours. Its lead asset, vididencel, has the potential to be a disruptive therapy in the maintenance setting for acute myeloid leukaemia. Most recently the company announced positive Phase II data from its ADVANCE II trial (presented at the American Society of Hematology 2023 meeting) and we look forward to the CADENCE combination trial. The company also has a second asset (ilixadencel) in soft tissue sarcoma (planned Phase II trial).

IO is a frenetic pharmaceutical development area with many clinical combination studies being conducted by pharmaceutical and biotech companies. Investors should expect relatively rich newsflow from this subsector over the next few years.